Adamis Pharmaceuticals Stock Rises Strongly Amid FDA Approval Expectation

Adamis Pharmaceuticals Corporation (ADMP) was up 33% to $0.7389, while the price has achieved almost 45% in a week. Today, the corporation made a significant statement by filing a Fast Track application to the U.S. Food and Drug Administration (FDA). The purpose is to treat and prevent the drug Tempol. What is the Tempol? Tempol is antiviral, anti-inflammatory, and antioxidant activity. According to the corporation, it is currently being tested in adult patients with COVID-19 infection as part of a phase 2/3 clinical research. Before this, the FDA approved antiviral drugs and believed that tempol could satisfy the medicine thanks to its unique mechanism.

Hence, in connection with the collaboration with researchers at Stanford University, it was reported that Tempol affects a strong, broad anti-cytokine activity in-vitro. Furthermore, this may prove to be a valuable strategy for treating COVID-19 infection. In the coming month, the price of ADMP stock may jump to highs. Actively observing the company’s price movement or the statics, it outperforms well with a 107$ million market cap.